Oral contraceptives (OCs) are the most widely used contraception method, and there is increasing interest in their effects on cognition, affect, and brain structure and function. Since women are not randomly assigned to OC use or non-use, it is unclear if previously-reported differences between OC users and naturally cycling (NC) women are due to sex hormones or to personal characteristics associated with pill use. The aim of this study was to fill this knowledge gap by comparing OC users and NC women on the Big Five personality factors. Participants came from two independent, large samples. The first contained 148 OC users and 93 NC women, and the second contained 247 OC users and 148 NC women. Consistent across both samples, multivariate analyses of covariance (with the five personality factors as dependent variables and age as a covariate) revealed no significant differences between OC users and NC women in personality, with absolute values of univariate effect sizes averaging d = .09. The pattern of results did not change when reason for OC use was considered, and users of different types of OCs did not differ from each other in personality. This well-powered study did not find personality differences between OC users and NC women in two independent samples, suggesting that previously-reported differences in cognition, affect, and the brain may be linked to neuroendocrinology.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.psyneuen.2018.09.034 | DOI Listing |
J Am Coll Health
January 2025
Department of Psychiatry, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Objective: This mixed-methods study examined attitudes, barriers, and preferences for mobile mental health interventions among first-year college students.
Participants: 351 students (64% women; 51% non-Hispanic White; 66% Heterosexual) from two campuses completed self-report assessments and 10 completed individual semi-structured interviews.
Methods: Paired t-tests compared attitudes for various mHealth applications and logistic regressions examined sociodemographic and clinical characteristics of mental health app users.
Comput Struct Biotechnol J
November 2024
Intellicode Cooperation, Republic of Korea.
Conventional personal health record (PHR) management systems are centralized, making them vulnerable to privacy breaches and single points of failure. Despite progress in standardizing healthcare data with the FHIR format, hospitals often lack efficient platforms for transferring PHRs, leading to redundant tests and delayed treatments. To address these challenges, we propose a decentralized PHR management system leveraging Personal Data Stores (PDS) and Decentralized Identifiers (DIDs) in line with the Web 3.
View Article and Find Full Text PDFCureus
December 2024
Cardiology, Riverside Community Hospital, Riverside, USA.
Background: Methamphetamine abuse is a public health problem across the world, and the cardiovascular system experiences a significant effect on the myocardium over time. Methamphetamine is a common cause of heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF). The prevalence and risk factors for HFpEF and HFrEF in this patient population remain unclear.
View Article and Find Full Text PDFInt J Cancer
January 2025
Department of Research, Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway.
Cancer diagnosis and therapy cause stress to the body. Preclinical studies have shown that stress hormones can stimulate tumor progression and metastasis by interacting with β-adrenergic receptors, and that β-blockers can inhibit those processes. We assessed if β-blocker use was associated with survival in a nationwide cohort of women with epithelial ovarian cancer (EOC).
View Article and Find Full Text PDFContraception
January 2025
MSI Reproductive Choices, London, England, United Kingdom.
Objective: We sought to develop consensus recommendations for measurement and analysis of data on contraceptive-induced menstrual changes (CIMCs) in contraceptive clinical trials. We built upon previous standardization efforts over the last 50 years and prioritized input from a variety of global experts and current regulatory authority guidance on patient-reported outcomes.
Study Design: We completed a formal consensus-building process with an interdisciplinary group of 57 experts from 30 organizations and 14 countries in five global regions who work across academia, nonprofit research organizations, the pharmaceutical industry, and funding agencies.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!